Global Respiratory Disease Vaccine Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Respiratory Disease Vaccine Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Oct 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Respiratory Disease Vaccine Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2025 –2031
Diagram Market Size (Base Year)
USD 23.42 Billion
Diagram Market Size (Forecast Year)
USD 34.93 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Bavarian Nordic
  • Bayer AG
  • AstraZeneca
  • Bio Farma
  • Dynavax Technologies

Global Respiratory Disease Vaccine Market, By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine), Vaccine (MMR, PPSV23, DTaP, Respiratory Syncytial Virus (RSV), Haemophilus Influenzae Type B (Hib)), Disease Type (Tuberculosis, Pertussis, Influenza Virus, Streptococcus Pneumoniae (Pneumonia), Chronic Obstructive Pulmonary Disease (COPD), Diphtheria, Others), Age (Infant, Adolescent, Adult), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.

 Respiratory Disease Vaccine Market

Respiratory Disease Vaccine Market Analysis and Size

Respiratory diseases are the diseases that affects and lungs and other parts of respiratory system. It is caused due to passive smoking, smoking tobacco, infection, asbestos and other kinds of air pollution. Chronic respiratory diseases are the diseases of airways and other structures of the lungs. The treatment of these diseases only reduces the symptoms. Immunization is the most effective method against chronic respiratory diseases.

Data Bridge Market Research analyses that the respiratory disease vaccine market which was USD 92.23 billion in 2022, is expected to reach USD 70.30 billion by 2030, and is expected to undergo a CAGR of 5.7% during the forecast period of 2023 to 2030. “Viral vaccine” dominates the type segment of the respiratory disease vaccine market owing to the rising prevalence of respiratory disorders. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Respiratory Disease Vaccine Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

  • Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine), Vaccine (MMR, PPSV23, DTaP, Respiratory Syncytial Virus (RSV), Haemophilus Influenzae Type B (Hib)), Disease Type (Tuberculosis, Pertussis, Influenza Virus, Streptococcus Pneumoniae (Pneumonia), Chronic Obstructive Pulmonary Disease (COPD), Diphtheria, Others), Age (Infant, Adolescent, Adult), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Countries Covered

  • U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa

Market Players Covered

  • Bavarian Nordic (Denmark), Bayer AG (Switzerland), AstraZeneca (U.K.), Bio Farma (India), Dynavax Technologies (U.S.), Emergent BioSolutions Inc. (U.S.), Merck Sharp & Dohme Corp. (Japan), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Seqirus (U.K.),  Sanofi (France), Serum Institute of India Pvt. Ltd. (India), CSL Limited (Australia), Novavax, Inc. (U.S.), INOVIO Pharmaceuticals (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan)

Market Opportunities

  • Growing  awareness among the population
  • Rising technological advancements

Market Definition

A vaccine against respiratory diseases is a sort of immunisation made to guard against infections brought on by pathogens that mostly affect the respiratory system. These vaccinations lower the chance of acquiring respiratory disorders by encouraging the immune system to recognise and defend against particular respiratory invaders, such as bacteria or viruses. They serve as a preventative strategy to lessen illness severity, consequences, and respiratory infection spread.

Respiratory Disease Vaccine Market Dynamics

Drivers

  • Increasing Prevalence of Respiratory Diseases

There is a greater understanding of the need for respiratory disease vaccines as a result of the introduction of novel respiratory diseases such as the COVID-19 pandemic. This has increased funding for research and development of vaccinations to protect against both novel and old respiratory infection.

  • Rising Government Initiatives

The development of new and improved vaccinations is supported by increased funding for research and development in the field of respiratory illness vaccines. The uptake of vaccines is increased via government-led vaccination campaigns and initiatives targeting vulnerable populations, such as children and the elderly.

Opportunities

  • Growing Awareness Among the Population

Public awareness campaigns and educational efforts can enhance understanding of the benefits of respiratory disease vaccines, leading to higher vaccine acceptance rates.

  • Rising Technological Advancements

Advances in vaccine technology, such as mRNA and viral vector platforms, offer opportunities to accelerate vaccine development and improve vaccine efficacy and safety.

Restrains/Challenges

  • Strict Regulations

Meeting regulatory requirements for vaccine approval and licensure in different countries can be time-consuming and expensive, adding to the overall development costs.

  • Logistics and Cold Chain Challenges

Some vaccines for respiratory diseases need to be kept and distributed in a cold chain, which can be difficult in areas with poor infrastructure and resources. Although it might be logistically challenging, maintaining the integrity of vaccinations during storage and transportation is essential.

  • Complexity in Vaccine Development

The diversity of the pathogens involved (viruses, bacteria), and the infection’s ongoing evolution, make the development of vaccinations for respiratory disorders problematic. Increased expenses and extended development times may result from this complexity.

  • Evolving Pathogens

The creation of novel strains and varieties is caused by the fast evolution of respiratory infections such as influenza viruses. This necessitates ongoing evaluation and revision of vaccination formulations, which can be time- and resource-consuming.

This respiratory disease vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the respiratory disease vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Respiratory Disease Vaccine Market Scope

The respiratory disease vaccine market is segmented on the basis of type, vaccine, disease type, age, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Type

  • Viral Vaccine
  • Bacterial Vaccine
  • Combination Vaccine

Vaccine

  • MMR
  • PPSV23
  • DTaP
  • Respiratory Syncytial Virus (RSV)
  • Haemophilus Influenzae Type B (HIB)

Disease Type

Age Group

  • Infant
  • Adolescent
  • Adult

End-Users

  • Clinic
  • Hospital
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Respiratory Disease Vaccine Market Regional Analysis/Insights

Respiratory disease vaccine market is analyzed and market size information is provided by the type, vaccine, disease type, age, end-users and distribution channel as referenced above.

The countries covered in the respiratory disease vaccine market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa

North America dominates the respiratory disease vaccine market due to the presence of major key players, government support for R&D activities in the field of vaccination, high healthcare expenditure and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 due to the increasing research and development activities, rising investment in the healthcare sector and high prevalence of respiratory diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Respiratory disease vaccine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. The data is available for historic period 2015 to 2020.

Competitive Landscape and Respiratory Disease Vaccine Market Share Analysis

Respiratory disease vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to respiratory disease vaccine market research.

Some of the major players operating in the respiratory disease vaccine market are:

  • Bavarian Nordic (Denmark)
  • Bayer AG (Switzerland)
  • AstraZeneca (U.K.)
  • Bio Farma (India)
  • Dynavax Technologies (U.S.)
  • Emergent BioSolutions Inc. (U.S.)
  • Merck Sharp & Dohme Corp. (Japan)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Seqirus (U.K.)
  • Sanofi (France)
  • Serum Institute of India Pvt. Ltd. (India)
  • CSL Limited (Australia)
  • Novavax, Inc. (U.S.)
  • INOVIO Pharmaceuticals (U.S.)
  • Mitsubishi Tanabe Pharma Corporation (Japan)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Respiratory Disease Vaccine Market will be worth USD 70.30 billion by 2030.
The Respiratory Disease Vaccine Market growth rate is 5.7% during the forecast period.
Increasing Prevalence of Respiratory Diseases & Rising Government Initiatives are the growth drivers of the Respiratory Disease Vaccine Market.
The type, vaccine, disease type, age, end-users and distribution channel are the factors on which the Respiratory Disease Vaccine Market research is based.
Bavarian Nordic (Denmark), Bayer AG (Switzerland), AstraZeneca (U.K.), Bio Farma (India), Dynavax Technologies (U.S.), Emergent BioSolutions Inc. (U.S.), Merck Sharp & Dohme Corp. (Japan), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Seqirus (U.K.), Sanofi (France) are the major companies in the Respiratory Disease Vaccine Market.